Literature DB >> 16083461

Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines.

Gerald M Aronoff1, Michael J Brennan, Douglas D Pritchard, Brian Ginsberg.   

Abstract

OBJECTIVE: To review the evidence for dosing and efficacy of oral transmucosal fentanyl citrate in the management of pain and produce dosing guidelines.
DESIGN: The scientific literature pertaining to oral transmucosal fentanyl citrate was reviewed, focusing upon its pharmacology and clinical experience with use in cancer and noncancer pain. Emphasis was upon published, peer-reviewed English language articles.
RESULTS: Information was crucially examined and synthesized into guidelines for use and dosing of oral transmucosal fentanyl citrate in cancer and noncancer pain.
CONCLUSIONS: Oral transmucosal fentanyl citrate is a potent opioid delivery system, which, when used appropriately, is an effective treatment option for pain. Adherence to guidelines should promote its safe and efficacious use in a variety of clinical pain management settings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083461     DOI: 10.1111/j.1526-4637.2005.00045.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  8 in total

Review 1.  Fentanyl Formulations in the Management of Pain: An Update.

Authors:  Stephan A Schug; Sonya Ting
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 2.  Ensuring pain relief for children at the end of life.

Authors:  Marie-Claude Grégoire; Gerri Frager
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

Review 3.  Pharmacotherapy for breakthrough cancer pain.

Authors:  Sebastiano Mercadante
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

4.  Low-dose fentanyl does not alter muscle sympathetic nerve activity, blood pressure, or tolerance during progressive central hypovolemia.

Authors:  Mu Huang; Joseph C Watso; Luke N Belval; Frank A Cimino; Mads Fischer; Caitlin P Jarrard; Joseph M Hendrix; Carmen Hinojosa Laborde; Craig G Crandall
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-12-01       Impact factor: 3.619

5.  Low-dose fentanyl reduces pain perception, muscle sympathetic nerve activity responses, and blood pressure responses during the cold pressor test.

Authors:  Joseph C Watso; Mu Huang; Luke N Belval; Frank A Cimino; Caitlin P Jarrard; Joseph M Hendrix; Carmen Hinojosa-Laborde; Craig G Crandall
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-12-01       Impact factor: 3.210

6.  [Oral transmucosal fentanyl citrate for the treatment of breakthrough pain. Results of a non-interventional study (NIS)].

Authors:  R Zarth; M Ehmer; H-B Sittig
Journal:  Schmerz       Date:  2007-11       Impact factor: 1.107

7.  The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.

Authors:  Sebastiano Mercadante; Giampiero Porzio; Federica Aielli; Lucilla Averna; Corrado Ficorella; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2013-04-07       Impact factor: 3.603

8.  In vitro and in vivo evaluation of a sublingual fentanyl wafer formulation.

Authors:  Stephen C B Lim; Michael J Paech; Bruce Sunderland; Yandi Liu
Journal:  Drug Des Devel Ther       Date:  2013-04-12       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.